1. Aberg-Wistedt Å, Cressell T, Lidberg Y, Liljenberg B, Ösby U. Two-year outcome of team-based intensive case management for patients with schizophrenia. Psychiatr Serv 1995;46:1263-1266.

2. Andrews G, Hall W, Goldstein G, Lapsley H, Bartels R, Silove D. The economic costs of schizophrenia: implications for public policy. Arch Gen Psychiatry 1985;42:537-543.

3. Anton SF, Revicki DA. The use of decision analysis in the pharmacoeconomic evaluation of an antidepressant: a cost-effectiveness study of Nefazodone. Psychopharmacol Bull 1995;31:249-258.

4. Awad AG. Quality of life of schizophrenic patients on medications and implications for new drug trials. Hosp Community Psychiatry 1992;43:262-265.

5. Bloom B. Issues in mandatory economic assessment of pharmaceuticals. Health Aff (Millwood) 1992;11:197-201.

6. Carpenter WT, Hanlon TE, Heinrichs DW, et al. Continuous versus targeted medication in schizophrenic outpatients: outcome results. Am J Psychiatry 1990;147:1138-1148.

7. Davis R, Wilde MI. Sertraline: a pharmacoeconomic evaluation of its use in depression. PharmacoEconomics 1996;10:409-431.

8. Drummond GW, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programs. Oxford, England: Oxford University Press, 1987.

9. Drummond M. Cost-of-illness studies: a major headache? PharmacoEconomics 1992;2:1-4.

10. Drummond MF. Basing prescription drug payment on economic analysis: the case of Australia. Health Aff (Millwood) 1992;11:191-196.

11. Drummond MF, Davies L. 1991. Economic analysis alongside clinical trials: revisiting the methodological issues. Int J Technol Assess Health Care 1991;7:561-573.

12. Eisenberg JM, Glick H, Koffer H. Pharmacoeconomics: economic evaluation of pharmaceuticals. In: Strom B, ed. Pharmacoepidemiology. New York: Churchill Livingston, 1989.

13. Elixhauser A. et al., Health care cost-benefit and cost-effectiveness analysis from 1979 to 1990: a bibliography. Med Care Supplement July 1993;7:J557-J5 138.

14. Feeny D, Labelle R, Torrance G. Integrating economic evaluations and quality of life assessments. In: Spilker B, ed. Quality of life assessments in clinical trials. New York: Raven Press, Ltd., 1990;71-83.

15. Frank E, Kupfer D, Perel J, et al. Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1990;47:1093-1099.

16. Freund DA, Evans D, Henry D, Dittus R. Implications of the Australian guidelines for the United States. Health Aff (Millwood) 1992;11:202-206.

17. Goldberg D. Cost-effectiveness in the treatment of patients with schizophrenia. Acta Psychiatr Scand 1994;89:89-92.

18. Grabowski H, Hansen R. Economic scales and tests. In: Spilker B, ed. Quality of life assessments in clinical trials. New York: Raven Press, Ltd., 1990;61-69.

19. Gregoire J, de Leval N, Mesters P, Czarka M. Validation of the quality of life in depression scale in a population of adult depressive patients aged 60 and above. Qual Life Res 1994;3:13-19.

20. Guyatt G, Jaeschke R. Measurements in clinical trials: choosing the appropriate approach. In: Spilker B, ed. Quality of life assessments in clinical trials. New York: Raven Press, Ltd., 1990;37-46.

21. Hatziandreu EJ, Brown RE, Revicki DA, et al. Cost utility of maintenance treatment of recurrent depression with sertraline versus episodic treatment with dothiepin. PharmacoEconomics 1994;5:249-264.

22. Heinrichs DW, Hanlon TE, Carpenter WT, Jr. The quality of life scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 1984;10:388-398.

23. Henderson-James D, Pilker B. An industry perspective. In: Spilker B, ed. Quality of life assessments in clinical trials. New York: Raven Press, Ltd., 1990;183-192.

24. Hogan TP, Awad AG. Subjective response to neuroleptics and outcome in schizophrenia: a re-examination comparing two measures. Psychol Med 1992;22:347-352.

25. Honigfeld G, Patin J. A 2-year clinical and economic follow-up of patients on clozapine. Hosp Community Psychiatry 1990;41:882-885.

26. Jönsson B, Bebbington PE. What price depression? The cost of depression and the cost-effectiveness of pharmacological treatment. Br J Psychiatry 1994;164:665-673.

27. Kamlet MS, Paul N, Greenhouse J, Kupfer D, Frank E, Wade M. Cost utility analysis of maintenance treatment for recurrent depression. Control Clin Trials 1995;16:17-40.

28. Lehman AF, Burns BJ. Severe mental illness in the community. In: Spilker B, ed. Quality of life assessments in clinical trials. New York: Raven Press, Ltd., 1990.

29. Lonnqvist J, Sintonen H, Syvalahti E, et al. Antidepressant efficacy and quality of life in depression: a double-blind study with moclobemide and fluoxetine. Acta Psychiatr Scand 1994;89:363-369.

30. Lurie N, Moscovice IS, Finch M, Christianson JB, Popkin MK. Does capitation affect the health of the chronically mentally ill? Results from a randomized trial. JAMA 1992;267:3300-3304.

31. Lyons JS, Larson DB, Hromco J. Clinical and economic evaluation of benzodiazepines. PharmacoEconomics 1992;2:397-407.

32. Marder SR, Van Putten T, Mintz J, et al. Costs and benefits of two doses of fluphenazine. Arch Gen Psychiatry 1984; 41:1025-1029.

33. Mauskopf JA, Simeon GP, Miles MA, Westlund RE, Davidson JRT. Functional status in depressed patients: the relationship to disease severity and disease resolution. J Clin Psychiatry 1996; 57:588-592.

34. Meltzer HY, Burnett S, Bastani B, Ramirez LF. Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hosp Community Psychiatry 1990;41:892-897.

35. Meltzer HY, Cola P, Way L, et al. Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia. Am J Psychiatry 1993;150:1630-1638.

36. Mesters P, Cosyns P, Dejaiffe G, et al. Assessment of quality of life in the treatment of major depressive disorder with fluoxetine, 20 mg, in ambulatory patients aged over 60 years. Int Clin Psychopharmacol 1993;8:337-340.

37. Mintz J, Mintz LI, Arruda MJ, Hwang SS. Treatments of depression and the functional capacity to work. Arch Gen Psychiatry 1992;49:761-768.

38. Ray WA, Griffin MR, Avorn J. Evaluating drugs after their approval for clinical use. N Engl J Med 1993;329:2029-2032.

39. Reifman A, Wyatt RJ. Lithium: a brake in the rising cost of mental illness. Arch Gen Psychiatry 1980;37:385-388.

40. Revicki D. Relationship between health utility and psychometric health status measures. Med Care 1992;30:274-282.

41. Revicki DA, Brown RE, Palmer W, et al. Modeling the cost effectiveness of antidepressant treatment in primary care. PharmacoEconomics 1995;8:524-540.

42. Revicki DA, Luce BR, Weschler JM, Brown RE, Adler MA. Cost-effectiveness of clozapine for treatment-resistant schizophrenic patients. Hosp Community Psychiatry 1990;41:850-854.

43. Revicki DA, Murray M. Assessing health-related quality of life outcomes of drug treatments for psychiatric disorders. CNS Drugs. 1994;1:465-476.

44. Revicki DA, Turner R, Brown R, Martindale JJ. Reliability and validity of a health-related quality of life battery for evaluating outpatient antidepressant treatment. Qual Life Res 1992;1:257-266.

45. Simon G, Wagner E, VonKorff M. Cost-effectiveness comparisons using "real world" randomized trials: the case of new antidepressant drugs. J Clin Epidemiol 1995;48:363-373.

46. Simon GE, VonKorff M, Heiligenstein JH, et al. Initial antidepressant choice in primary care: effectiveness and cost of fluoxetine vs tricyclic antidepressants. JAMA. 1996;275:1897-1902.

47. Simpson CJ, Hyde CE, Faragher EB. The chronically mentally ill in community facilities: a study of quality of life. Br J Psychiatry 1989;154:77-82.

48. Sloan F, Grabowski H, eds. The impact of cost-effectiveness on public and private policies in health care: an international perspective. Soc Sci Med special issue, 45(4), August 1977.

49. Souêtre E, Martin P, Lozet H, Monteban H. Quality of life in depressed patients: comparison of fluoxetine and major tricyclic antidepressants. Int Clin Psychopharmacol 1996;11:45-52.

50. Stoudemire A, Frank R, Hedemark N, Kamlet M, Blazer D. The economic burden of depression. Gen Hosp Psychiatry 1986;8:387-394.

51. Thompson M. Willingness to pay and accept risks to cure chronic disease. Am J Public Health 1986;76(4):392-396.

52. Thompson M, Read JL, Liang M. Feasibility of willingness-to-pay measurement for chronic arthritis. Med Decis Making 1984;4:195-215.

53. Torrance GW. Measurement of health state utilities for economic appraisal. J Health Econ 1986;5:1-30.

54. Torrance GW, Boyle MH, Horwood SP. Application of multi-attribute utility theory to measure social preferences for health states. Oper Res 1982;30:1043-1069.

55. Turner R. Quality of life: experience with sertraline. Int Clin Psychopharmacol 1994;9(Suppl 3):27-31.

56. Van Putten T, May PRA, Marder SR, Wittmann LA. Subjective response to antipsychotic drugs. Arch Gen Psychiatry 1981;38:187-190.

57. Weinstein MC, Coxson PG, Williams LW, Pass TM, Statson WB, Goldman L. Forecasting coronary heart disease incidence, mortality, and cost: the coronary heart disease policy model. Am J Pub Health 1987;77:1417-1426.

58. Whalley D, McKenna SP. Measuring quality of life in patients with depression or anxiety. PharmacoEconomics 1995;8:305-315.